Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
20/05/2026 16:04
May 20 (Reuters) - Ryvu Therapeutics SA RVU.WA: UPDATES ROMACYCLIB DEVELOPMENT STRATEGY TO FOCUS ON RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PLANS TO ENROLL ABOUT 30 ADDITIONAL PATIENTS IN RIVER-81 STUDY TO SUPPORT POTENTIAL PARTNERING TRANSACTION RECENT DEVELOPMENT DECISIONS ARE NOT EXPECTED TO HAVE A MATERIAL NEGATIVE IMPACT ON 2026-2027 FINANCIAL OUTLOOK Source text: ID:nEM7pGw37a Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project